Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug

  • The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc VIR and GlaxoSmithKline Plc GSK for treating mild-to-moderate COVID-19 in people aged 12 years and older.
  • The EUA comes after Vir’s antibody proved 85% effective at preventing hospitalization in high-risk, newly diagnosed COVID-19 patients.
  • The antibody, Sotrovimab, is not authorized for hospitalized patients due to COVID-19 or require oxygen therapy.
  • The antibody treatment will be available for COVID-19 patients in the coming weeks, GSK and Vir said, adding that they plan to submit a marketing application to the FDA in the second half of 2021.
  • Last week, the European Union’s CHMP backed the use of Sotrovimab for COVID-19 patients who were at risk of severe disease and did not need supplemental oxygen.
  • Price Action: VIR shares are up 9.27% at $50, while GSK shares are down 0.67% at $38.45 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCovid-19COVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!